Showing 1951-1960 of 2105 results for "".
- Virtual Programs and Events Available to Support PD Community Through Ongoing COVID-19 Pandemichttps://practicalneurology.com/news/virtual-programs-and-events-available-to-support-pd-community-through-ongoing-covid-19-pandemic/2469361/The Parkinson's Foundation has continued to host virtual programs and events to support the Parkinson disease (PD) community during the ongoing COVID-19 pandemic. This year, their signature event Fall Moving Day will be online. The Foundation has new events prepared for PD Health@Home, a virt
- Soticlestat Reduces Seizure Frequency in Children with Dravet or Lennox-Gastaut Syndromehttps://practicalneurology.com/news/soticlestat-reduces-seizure-frequency-in-children-with-dravet-or-lennox-gastaut-syndrome/2469360/Data from a randomized phase 2 ELEKTRA study (NCT03650452) (Takeda Pharmaceutical, New York, NY) showed soticlestat treatment reduced seizure frequency in children with Dravet syndrome (DS) or Len
- FDA Gives Green Light to Trehelose Phase 2b/3 Trial for ALShttps://practicalneurology.com/news/fda-gives-green-light-to-trehelose-phase-2b3-trial-for-als/2469350/The Food and Drug Administration (FDA) has issued a may proceed notice, allowing the initiation of a phase 2b/3 trial studying trehalose (SLS-005, Seelos Therapeutics, New York, NY) for the treatment of amyotrophic lateral sclerosis (ALS). Familial ALS is caused by mutations in th
- DHODH Inhibitor Reduces Lesions Significantly in Relapsing-Remitting MShttps://practicalneurology.com/news/dhodh-inhibitor-reduces-lesions-significantly-in-relapsing-remitting-ms/2469343/A phase 2 clinical trial (NCT03846219) of a selective oral Dihydroorotate dehydrogenase (DHODH) inhibitor (IMU-838; Immunic, New York, NY) provided a significant reduction in lesions in participan
- FDA Approves ppCBD to Treat Seizures Associated with Tuberous Sclerosis Complexhttps://practicalneurology.com/news/fda-approves-ppcbd-to-treat-seizures-associated-with-tuberous-sclerosis-complex/2469341/The Food and Drug Administration (FDA) has approved prescription pharmaceutical cannabidiol (ppCBD) (Epidiolex; GW Pharmaceuticals, Carlsbad, CA) oral solution to treat seizures associated with tuberous sclerosis complex (TSC) in patients age 1 year or more. Along with this new indication, the ag
- FDA Approves New Oxybates Compound for Cataplexy or Excessive Daytime Sleepiness of Narcolepsyhttps://practicalneurology.com/news/fda-approves-new-oxybate-compound-for-cataplexy-or-excessive-daytime-sleepiness-of-narcolepsy/2469330/The Food and Drug Administration (FDA) approved a calcium, magnesium, potassium, and sodium oxybates oral solution (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in individuals age 7 years and more with n
- FDA Approves Fenfluramine for Treatment of Seizures Associated with Dravet Syndromehttps://practicalneurology.com/news/fda-approves-fenfluramine-for-treatment-of-seizures-associated-with-dravet-syndrome/2469308/The Food and Drug Administration (FDA) has approved fenfluramine (Fintepla; Zogenix, Emeryville, CA), oral solution for treatment of seizures associated with Dravet syndrome (DS) in individuals age 2 years or more. Fenfluramine will be launched through a restricted distribution program, called th
- Phase 2 Clinical Trial for Stem-Cell Treatment of Alzheimer Disease Plannedhttps://practicalneurology.com/news/phase-2-clinical-trial-for-stem-cell-treatment-of-alzheimer-disease-planned/2469305/A phase 2 clinical trial to evaluate the safety and efficacy of treatment in individuals with prodromal to mild Alzheimer disease (AD) is planned for the autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY). The program is be
- Children Treated With Nusinersen Continue Meeting Developmental Motor Milestoneshttps://practicalneurology.com/news/children-treated-with-nusinersen-continue-meeting-developmental-motor-milestones/2469290/When used as prolonged treatment for children with spinal muscular atrophy (SMA), nusinersen (Spinraza; Biogen Inc., Cambridge, MA) results in progressive improvements in motor function. The early and continuous treatment with nusinersen for 4.8 years enabled unprecedented survival in participant
- Investigation of Foralumab for Alzheimer Disease Treatment Will Continue to Phase 2https://practicalneurology.com/news/investigation-of-foralumab-for-alzheimer-disease-treatment-will-continue-to-phase-2/2469286/Nasally administered foralumab (Tiziana Life Sciences, New York, NY) has showed delays in disease processes underlying the progression of Alzheimer disease (AD) in animal models . Based on those results, the investigation of foralumab for AD will continue to phase 2 clinical trials. Foralum